Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 01:32 pm IST
Share
Daewon Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 109.23 million compared to KRW 199.12 million a year ago. Net income was KRW 5,455.53 million compared to KRW 11,072.14 million a year ago. Basic earnings per share from continuing operations was KRW 260 compared to KRW 522 a year ago. Diluted earnings per share from continuing operations was KRW 252 compared to KRW 510 a year ago. Basic earnings per share was KRW 260 compared to KRW 522 a year ago. Diluted earnings per share was KRW 252 compared to KRW 510 a year ago.
For the nine months, sales was KRW 660.62 million compared to KRW 421.54 million a year ago. Net income was KRW 23,167.48 million compared to KRW 28,979.21 million a year ago. Basic earnings per share from continuing operations was KRW 1,105 compared to KRW 1,366 a year ago. Diluted earnings per share from continuing operations was KRW 1,077 compared to KRW 1,334 a year ago. Basic earnings per share was KRW 1,105 compared to KRW 1,366 a year ago. Diluted earnings per share was KRW 1,077 compared to KRW 1,334 a year ago.
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
DAEWON PHARMACEUTICAL CO., LTD. 
